演題抄録

一般演題 (示説)

開催概要
開催回
第54回・2016年・横浜
 

Tumor responses following a switch from non-steroidal (bicalutamide) to steroidal (cyproterone acetat) antiandrogen deprivation therapy

演題番号 : P25-11

[筆頭演者]
Mermershtain Wilmosh:1 
[共同演者]
Ariad Samuel:1、Rouvinov Keren:1

1:Soroka University Medical Center, Israel・Department of Oncology・Onco-Urology Service

 

Background: We hypothesized that a 'switch' from NSADT (non-steroidal androgen deprivation therapy) to SADT (steroidal androgen deprivation therapy) would induce secondary responses in patients with at PSA progression.
Purpose: To evaluate efficacy of Cyproterone acetate (CPA) in patients who progressed after treatment with Bicalutamide.
Patients /Methods: We performed a switch in patients with at PSA progression on NSADT (Bicalutamide) to SADT (Cyproterone acetate). Patients were monitored for secondary declines in PSA, radiological tumor regression and toxicity. Twenty eight eligible patients (pts) with advanced prostate cancer were treated with LH-RH analogue and steroidal anti-androgen CPA after failure of treatment with LH-RH analogue and non-steroidal antiandrogen (Bicalutamide). CPA was given orally 200mg/day. Treatment continued until progression. The mean age was 72 years (range 52-86). ECOG performance status was 1 in 25 pts (89%), and 2 in 3pts (11%) .25pts (89%) have metastatic disease and 3pts (11%) biochemical failure only. 20 pts have bone metastasis (mts), and 5pts visceral mts. The mean PSA level in the beginning of CPA was 30.5 ng/ml (range 1.15-122).
Results: Six pts (33.3%) responded, 2pts (11.1%) have stable disease (SD), and 10pts (55.5%) progressive disease (PD). PSA doubling time (PSA DT) in responders were 7months, with only 2.3 months in non responders.

Conclusions: According to our experience CPA given with LH-RH analogue in patients who progressed after LH-RH analogue and non-steroidal antiandrogen was well tolerated and may have some benefit in patients with advanced prostate cancer.

キーワード

臓器別:前立腺・男性生殖器

手法別:臨床試験

前へ戻る